CLINICAL TRIALS PROFILE FOR IOFLUPANE I-123
✉ Email this page to a colleague
All Clinical Trials for IOFLUPANE I-123
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01141023 ↗ | Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression | Active, not recruiting | Institute for Neurodegenerative Disorders | Phase 2 | 2010-06-01 | This is a observational, multi-center study to assess progression of clinical features, imaging and biologic biomarkers in Parkinson disease (PD) patients compared to healthy controls (HC) and in PD patient subtypes. The primary objective of this study is to identify clinical, imaging and biologic markers of PD progression for use in clinical trials of disease-modifying therapies. |
| NCT01141023 ↗ | Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression | Active, not recruiting | Ken Marek, MD | Phase 2 | 2010-06-01 | This is a observational, multi-center study to assess progression of clinical features, imaging and biologic biomarkers in Parkinson disease (PD) patients compared to healthy controls (HC) and in PD patient subtypes. The primary objective of this study is to identify clinical, imaging and biologic markers of PD progression for use in clinical trials of disease-modifying therapies. |
| NCT01453127 ↗ | DaTSCAN Imaging in Aging and Neurodegenerative Disease | Enrolling by invitation | Mayo Clinic | Phase 4 | 2011-10-01 | The investigators propose using DaTscan in patients with REM sleep behavior disorder (RBD), mild cognitive impairment (MCI), Parkinson's disease (PD), dementia with Lewy bodies (DLB), Alzheimer's disease (AD), and other neurodegenerative syndromes and disorders, to test several hypotheses - some confirmatory, and some novel. Such use will provide new data on the potential clinical and research utility of DaTscan in neurodegenerative diseases. The findings on DaTscan will be correlated with clinical diagnoses and other multimodal imaging studies (e.g., MRI, MRS, FDG-PET, and amyloid-PET) to enhance our understanding of neurodegenerative diseases. |
| NCT03185182 ↗ | Diagnostic Imaging for Clear Cell Renal Cell Carcinoma | Terminated | Lund University | Phase 2 | 2017-07-14 | The main objective is to study whether imaging detection of the biomarker DAT can be used to detect kidney tumors identified by computer tomography (CT), which are pathologically assesses as being of the clear cell subtype. |
| NCT03185182 ↗ | Diagnostic Imaging for Clear Cell Renal Cell Carcinoma | Terminated | Region Skane | Phase 2 | 2017-07-14 | The main objective is to study whether imaging detection of the biomarker DAT can be used to detect kidney tumors identified by computer tomography (CT), which are pathologically assesses as being of the clear cell subtype. |
| NCT03582488 ↗ | Longitudinal Imaging Biomarkers of Disease Progression in DLB | Enrolling by invitation | Kejal Kantarci | Phase 4 | 2018-06-25 | The Researchers are trying to determine the paths of change in imaging biomarkers of Dementia with Lewy bodies (DLB) and their associations with rate of cognitive and functional decline. |
| NCT03775096 ↗ | Adrenergic Blockers for Cardiac Changes in Early Parkinson's Disease | Recruiting | Michele Tagliati, MD | Phase 2 | 2019-04-04 | REM Behavior Sleep Disorder (RBD) is a sleep disorder causing people to 'act out' their dreams. A high percentage of individuals with idiopathic RBD (iRBD) are known to develop conditions affecting the neurons in the brain such as Parkinson's disease (PD). Based on the increased risk to develop PD, individuals with iRBD are currently considered ideal candidates for therapies that can possibly protects brain cells, due to the critical window of opportunity to intervene early before brain cell loss progresses significantly. Early changes of PD are associated with a number of symptoms including loss of smell, constipation, anxiety and depression. In addition, early heart and brain abnormalities can be visualized using specialized imaging techniques called 123I-MIBG myocardial scintigraphy (MIBG) and dopamine transporter (DAT) single photon emission computerized tomography (SPECT) respectively. The combined presence of certain symptoms and the use of these imaging techniques are considered early markers of PD in individuals with iRBD. In other conditions, like heart failure, MIBG abnormalities are reversed by drugs able to block excessive adrenergic stimulation, known as beta-blockers. In this study the investigators want to learn about the effect of treatment with the beta-blocker carvedilol on MIBG abnormalities found in iRBD patients at risk to develop PD. The investigators believe that reversing the MIBG abnormality might prelude to a slowing of the neurodegenerative process. This drug is approved by the U.S. Food and Drug Administration (FDA) for congestive heart failure, hypertension and left ventricular dysfunction after myocardial infarction. However, carvedilol is not approved by the FDA in patients with iRBD at risk for PD. The available doses for this drug oral formulations are 3.125mg, 6.25mg, 12.5mg and 25mg. Changes visualized with the MIBG imaging technique will be correlated to the presence and severity of neurological (i.e. tremors, stiffness, slow movements, walking difficulties) and other symptoms associated with PD (i.e. abnormal smell, constipation, depression, color vision abnormalities), as measured by specific clinical scales and exams. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for IOFLUPANE I-123
Condition Name
Clinical Trial Locations for IOFLUPANE I-123
Trials by Country
Clinical Trial Progress for IOFLUPANE I-123
Clinical Trial Phase
Clinical Trial Sponsors for IOFLUPANE I-123
Sponsor Name
